These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21504243)

  • 21. Globalisation, health policy and the exercise of power--a second opinion on Gilbert and Gilbert (2004).
    Thomas S; Thiede M
    Health Policy; 2005 Jun; 72(3):261-4. PubMed ID: 15862634
    [No Abstract]   [Full Text] [Related]  

  • 22. [Economic evaluations more and more important in healthcare decision making. Costs must be balanced against benefits also in studies on health economics].
    Lundkvist J
    Lakartidningen; 2006 Nov 15-21; 103(46):3624-7. PubMed ID: 17153872
    [No Abstract]   [Full Text] [Related]  

  • 23. Transparent and reproducible reports of economic evaluations of clinical pharmacy services: a goal for the future?
    Hoffman JM; Meek PD; Touchette DR; Vermeulen LC; Schumock GT
    Am J Health Syst Pharm; 2009 Mar; 66(5):442-3; author reply 443-4. PubMed ID: 19233988
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin.
    Lopert R; Lang DL; Hill SR
    J Clin Pharm Ther; 2003 Jun; 28(3):243-9. PubMed ID: 12795784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan.
    Hammad EA
    Value Health; 2016; 19(2):233-8. PubMed ID: 27021758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How Can Economics Advance Prevention?
    Glied S; Teutsch SM
    Am J Prev Med; 2016 May; 50(5 Suppl 1):S4-S5. PubMed ID: 27102857
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacoeconomics: integrating economic evaluation into clinical trials.
    Haycox A; Drummond M; Walley T
    Br J Clin Pharmacol; 1997 Jun; 43(6):559-62. PubMed ID: 9205814
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees.
    Hughes D; Reynolds DJ
    Clin Med (Lond); 2009 Oct; 9(5):490-2. PubMed ID: 19886115
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness analysis: from science to application.
    Berger ML; Teutsch S
    Med Care; 2005 Jul; 43(7 Suppl):49-53. PubMed ID: 16056009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of health economics in Vietnam: a tentative research agenda.
    Lindholm L; Thanh NX
    Scand J Public Health Suppl; 2003; 62():66-9. PubMed ID: 14578076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spanish recommendations on economic evaluation of health technologies.
    López-Bastida J; Oliva J; Antoñanzas F; García-Altés A; Gisbert R; Mar J; Puig-Junoy J
    Eur J Health Econ; 2010 Oct; 11(5):513-20. PubMed ID: 20405159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fiscal austerity and the health sector: the cost of adjustments.
    Paes-Sousa R; Schramm JMA; Mendes LVP
    Cien Saude Colet; 2019 Dec; 24(12):4375-4384. PubMed ID: 31778488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designing evaluation studies to optimally inform policy: what factors do policy-makers in China consider when making resource allocation decisions on healthcare worker training programmes?
    Wu S; Legido-Quigley H; Spencer J; Coker RJ; Khan MS
    Health Res Policy Syst; 2018 Feb; 16(1):16. PubMed ID: 29471840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The power of pharmacoeconomics.
    Healthc Exec; 2000; 15(1):44-5. PubMed ID: 11067028
    [No Abstract]   [Full Text] [Related]  

  • 36. Presenting economic information for decision making.
    Pelc A
    Pharmacoeconomics; 1994 Oct; 6(4):346-51. PubMed ID: 10147471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling for health care and other policy decisions: uses, roles, and validity.
    Johnson FR; Paul JE
    Value Health; 2002; 5(1):62-3; author reply 61-2. PubMed ID: 11873387
    [No Abstract]   [Full Text] [Related]  

  • 38. Incorporation of uncertainty in health economic modelling studies.
    O'Hagan A; McCabe C; Akehurst R; Brennan A; Briggs A; Claxton K; Fenwick E; Fryback D; Sculpher M; Spiegelhalter D; Willan A
    Pharmacoeconomics; 2005; 23(6):529-36. PubMed ID: 15960550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Application of cost-effectiveness analysis of health care interventions in developing countries. A case study in Mauritius].
    Shibuya K; Kunii O
    Nihon Koshu Eisei Zasshi; 2000 Dec; 47(12):1018-28. PubMed ID: 11201144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cheap drugs pulled despite wealth gap in middle-income countries.
    Waters H
    Nat Med; 2011 Sep; 17(9):1023. PubMed ID: 21900898
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.